Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
CadonilimabClear Cell Renal Cell CarcinomaNeoadjuvant Therapy
Interventions
DRUG

Cadonilimab Combined With Lenvatinib

"3.7.1 Lenvatinib Treatment Lenvatinib (8mg \[body weight \< 60 kg\] or 12 mg \[body weight ≥ 60 kg\]) orally once daily, with or without food.~3.7.2 Intravenous Infusion of Cardonilli (Injection) Infuse Cardonilli at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles."

Trial Locations (1)

0755

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER